These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

899 related articles for article (PubMed ID: 21964893)

  • 1. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
    Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
    Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients.
    Tsai HL; Lin CH; Huang CW; Yang IP; Yeh YS; Hsu WH; Wu JY; Kuo CH; Tseng FY; Wang JY
    Int J Clin Exp Pathol; 2015; 8(2):1900-10. PubMed ID: 25973082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme).
    Avallone A; Piccirillo MC; Aloj L; Nasti G; Delrio P; Izzo F; Di Gennaro E; Tatangelo F; Granata V; Cavalcanti E; Maiolino P; Bianco F; Aprea P; De Bellis M; Pecori B; Rosati G; Carlomagno C; Bertolini A; Gallo C; Romano C; Leone A; Caracò C; de Lutio di Castelguidone E; Daniele G; Catalano O; Botti G; Petrillo A; Romano GM; Iaffaioli VR; Lastoria S; Perrone F; Budillon A
    BMC Cancer; 2016 Feb; 16():69. PubMed ID: 26857924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of standard chemotherapy and antiangiogenic therapy on plasma markers and endothelial cells in colorectal cancer.
    Ramcharan KS; Lip GY; Stonelake PS; Blann AD
    Br J Cancer; 2014 Oct; 111(9):1742-9. PubMed ID: 25211664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic profiling of CD133 is associated with response rate (RR) and progression-free survival (PFS) in patients with metastatic colorectal cancer (mCRC), treated with bevacizumab-based chemotherapy.
    Pohl A; El-Khoueiry A; Yang D; Zhang W; Lurje G; Ning Y; Winder T; Hu-Lieskoven S; Iqbal S; Danenberg KD; Kahn M; Teo JL; Shriki J; Stebbing J; Lenz HJ
    Pharmacogenomics J; 2013 Apr; 13(2):173-80. PubMed ID: 22231565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased levels of circulating endothelial progenitor cells in subjects with moderate to severe chronic periodontitis.
    Li X; Tse HF; Yiu KH; Jia N; Chen H; Li LS; Jin L
    J Clin Periodontol; 2009 Nov; 36(11):933-9. PubMed ID: 19799717
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of increased body mass index (BMI) on time to tumour progression (TTP) in unresectable metastatic colorectal cancer (mCRC) patients treated with bevacizumab-based therapy.
    Faruk Aykan N; Yildiz I; Sen F; Kilic L; Keskin S; Ciftci R; Karabulut S; Sakar B; Disci R
    Med Oncol; 2013; 30(3):679. PubMed ID: 23921648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a benefit from addiction to anti-VEGF therapy in patients with colorectal cancer?
    Saif MW
    Anticancer Res; 2013 Jun; 33(6):2377-80. PubMed ID: 23749885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of glycemic control on circulating endothelial progenitor cells and arterial stiffness in patients with type 2 diabetes mellitus.
    Yue WS; Lau KK; Siu CW; Wang M; Yan GH; Yiu KH; Tse HF
    Cardiovasc Diabetol; 2011 Dec; 10():113. PubMed ID: 22185563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
    Tol J; Punt CJ
    Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenesis therapy in second line metastatic colorectal cancer: similar but different.
    Saif MW
    Expert Opin Biol Ther; 2013 Nov; 13(11):1489-93. PubMed ID: 24050123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-angiogenic therapies for metastatic colorectal cancer.
    Wagner AD; Arnold D; Grothey AA; Haerting J; Unverzagt S
    Cochrane Database Syst Rev; 2009 Jul; (3):CD005392. PubMed ID: 19588372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial.
    Pineda E; Salud A; Vila-Navarro E; Safont MJ; Llorente B; Aparicio J; Vera R; Escudero P; Casado E; Bosch C; Bohn U; Pérez-Carrión R; Carmona A; Ayuso JR; Ripollés T; Bouzas R; Gironella M; García-Albéniz X; Feliu J; Maurel J
    Tumour Biol; 2017 Jun; 39(6):1010428317705509. PubMed ID: 28621236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant treatment of colorectal cancer with bevacizumab: the perioperative angiogenic balance is sensitive to systemic thrombospondin-1 levels.
    Brostjan C; Gebhardt K; Gruenberger B; Steinrueck V; Zommer H; Freudenthaler H; Roka S; Gruenberger T
    Clin Cancer Res; 2008 Apr; 14(7):2065-74. PubMed ID: 18381946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 'real-life' impact of adding bevacizumab to first-line therapy in metastatic colorectal cancer patients: a large Israeli retrospective cohort study.
    Hammerman A; Greenberg-Dotan S; Battat E; Feldhamer I; Bitterman H; Brenner B
    Acta Oncol; 2015 Feb; 54(2):164-70. PubMed ID: 25350524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidedness.
    Bencsikova B; Budinska E; Selingerova I; Pilatova K; Fedorova L; Greplova K; Nenutil R; Valik D; Obermannova R; Sheard MA; Zdrazilova-Dubska L
    BMC Cancer; 2019 Jul; 19(1):687. PubMed ID: 31307428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in circulating microRNA-126 during treatment with chemotherapy and bevacizumab predicts treatment response in patients with metastatic colorectal cancer.
    Hansen TF; Carlsen AL; Heegaard NH; Sørensen FB; Jakobsen A
    Br J Cancer; 2015 Feb; 112(4):624-9. PubMed ID: 25584492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low circulating level of CD133+KDR+cells in patients with systemic sclerosis.
    Mok MY; Yiu KH; Wong CY; Qiuwaxi J; Lai WH; Wong WS; Tse HF; Lau CS
    Clin Exp Rheumatol; 2010; 28(5 Suppl 62):S19-25. PubMed ID: 21050541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis.
    Zhao L; Zhang D; Ma H; Jin M; Huang F; Zhang T
    Panminerva Med; 2016 Mar; 58(1):48-58. PubMed ID: 26763741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of antiangiogenic agents in the treatment of patients with advanced colorectal cancer according to K-RAS status.
    García-Alfonso P; Grande E; Polo E; Afonso R; Reina JJ; Jorge M; Campos JM; Martínez V; Angeles C; Montagut C
    Angiogenesis; 2014 Oct; 17(4):805-21. PubMed ID: 24793846
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.